Lilly   4Q Revenues: $5.4 billion (+5%) 4Q Earnings: $478.4 million (+12%) FY Revenues: $20.0 billion (+2%) FY Earnings: $2.4 billion (+1%) Comments: Revenue in the U.S. increased 15% to $2.8 billion in the quarter. Growth in the quarter was primarily due to the inclusion of Novartis Animal Health revenue ($811.7 million, up 28%) and diabetes drugs Trulicity ($112.5 million), and Cyramza ($117.5 million), as well as Erbitux ($176.2 million, up 83%) due to the transfer of commercial...